Bio-Rad Laboratories, Inc. BIO.B Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| All Other Segments | $0-100% | $500K-85.7% | $3.5M-12.5% | $4M— | |
| Clinical Diagnostics | $1.56B+1.6% | $1.54B+3.3% | $1.49B+2.6% | $1.45B-4.3% | |
| Life Science | $1.02B-0.7% | $1.03B-12.8% | $1.18B-12.5% | $1.35B-3.8% | |
| Gross Profit by Business | |||||
| Clinical Diagnostics | $786.8M-1.2% | $796.5M+4.3% | $763.5M+1.2% | $754.5M— | |
| Life Science | $553.1M-5.0% | $582.4M-12.3% | $664M-18.5% | $814.5M— | |
| Total Assets by Business | |||||
| Clinical Diagnostics | $1.89B-3.3% | $1.96B— | —— | —— | |
| Life Science | $1.22B+2.2% | $1.19B— | —— | —— | |
| Cost of goods sold by Business | |||||
| Clinical Diagnostics | $775.3M+4.6% | $741.4M+2.1% | $725.8M+4.2% | $696.5M— | |
| Life Science | $468M+5.0% | $445.7M-13.4% | $514.4M-3.4% | $532.7M— | |
| Depreciation, Depletion and Amortization by Business | |||||
| Clinical Diagnostics | $90.4M+7.4% | $84.2M+1.3% | $83.1M+4.7% | $79.4M-4.1% | |
| Life Science | $75M+11.3% | $67.4M+7.3% | $62.8M+8.5% | $57.9M+5.7% | |
| Goodwill by Business | |||||
| Clinical Diagnostics | $1.68B+1.4% | $1.66B+0.6% | $1.65B+9.2% | $1.51B+8.0% | |
| Life Science | $1.81B+36.1% | $1.33B0.0% | $1.33B+0.1% | $1.33B+14.1% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | |||||
| Clinical Diagnostics | $10.1M+426% | -$3.1M— | —— | —— | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | |||||
| Clinical Diagnostics | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | |
| Life Science | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | |
| Goodwill, net by Business | |||||
| Clinical Diagnostics | $507.2M+4.7% | $484.5M+2.2% | $473.9M+41.6% | $334.7M+50.0% | |
| Life Science | $1.65B+41.3% | $1.17B0.0% | $1.17B+0.1% | $1.16B+16.5% | |
| Goodwill, Period Increase (Decrease) by Business | |||||
| Clinical Diagnostics | $10.1M+426% | -$3.1M— | —— | —— | |
| Life Science | $162.1M— | $0— | $0— | —— | |
| Net Sales by Geography | |||||
| Americas | $165.4M-2.3% | $169.3M+1.8% | $166.3M+7.1% | $155.3M-0.7% | |
| Asia Pacific | $513.3M-1.6% | $521.7M-7.1% | $561.8M-12.2% | $639.5M-7.1% | |
| Europe | $881.8M+5.7% | $834.1M+1.7% | $819.8M-3.8% | $851.9M-10.0% | |
| UNITED STATES | $1.02B-1.8% | $1.04B-7.3% | $1.12B-2.8% | $1.16B+2.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Rad Laboratories, Inc. break its business down?
- Bio-Rad Laboratories, Inc. (BIO.B) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Rad Laboratories, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
